Le Lézard
Classified in: Health
Subject: FVT

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference


DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.  

An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases ? often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

SOURCE Jazz Pharmaceuticals plc


These press releases may also interest you

at 04:00
The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2024 Prix Galien UK Award candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...

at 04:00
Globally, cardiovascular diseases due to atherosclerosis ? the build-up of plaque in arteries ? are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and...

at 03:33
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF)...

at 03:00
One in four people with pre-existing medical conditions (25%) say they will not declare all of their medical conditions when buying travel insurance, with 40% of these only declaring what they are currently being treated for. Of those that would not...

at 03:00
Viewpoint, the esteemed educational program hosted by renowned actor Dennis Quaid, is proud to announce a collaboration with Cedar Community in West Bend, Wisconsin for an upcoming episode that will shed light on the evolving journey of aging. Set to...

at 02:43
Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be...



News published on and distributed by: